How to Wean Off Tirzepatide: The Evidence-Based Tapering Protocol and What to Expect After Stopping

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide has a 5-day half-life, meaning gradual tapering over 4 to 8 weeks reduces rebound hunger and metabolic adaptation compared to abrupt discontinuation
• Published data shows 25% to 30% weight regain in the first year after stopping GLP-1 medications without structured maintenance, but behavioral intervention reduces this to 10% to 15%
• There is no physical withdrawal syndrome from stopping tirzepatide, but appetite normalization takes 2 to 4 weeks as GLP-1 receptor activity returns to baseline
• Cold-turkey discontinuation is medically safe for most patients but creates the hardest behavioral transition, while dose-halving every 2 weeks provides the smoothest metabolic bridge

Direct answer (40-60 words)

The safest way to wean off tirzepatide is to reduce your dose by 50% every 2 weeks until you reach the lowest available dose, then stop. This 4 to 8 week taper allows appetite hormones to normalize gradually. Abrupt discontinuation is medically safe but creates sharper rebound hunger. Most patients regain 10% to 30% of lost weight in the first year without maintenance behaviors.

Table of contents

1. Why most articles get the tapering question wrong
2. The pharmacology: why tirzepatide doesn't require tapering for safety
3. The behavioral case for tapering anyway
4. The three-tier tapering protocol based on treatment duration
5. What happens physiologically when you stop tirzepatide
6. Rebound weight gain: the published data on what to expect
7. The maintenance protocol that cuts regain by half
8. When cold-turkey discontinuation is the right choice
9. Symptoms during the taper and how to manage them
10. The decision tree: should you stop, pause, or reduce dose?
11. What we see in FormBlends discontinuation patterns
12. FAQ

Why most articles get the tapering question wrong

The majority of published content on stopping tirzepatide conflates two separate questions: medical necessity and behavioral optimization. They are not the same.

The medical question is simple: tirzepatide does not cause physical dependence. There is no withdrawal syndrome. You will not have seizures, dangerous blood pressure changes, or organ dysfunction if you stop abruptly. The FDA label for Mounjaro and Zepbound contains no tapering requirement. From a pure safety standpoint, you can stop today.

The behavioral question is harder: stopping a medication that has suppressed your appetite for months creates a sharp transition back to baseline hunger signaling. Your brain's reward response to food, which was dampened, returns to normal. Ghrelin (the hunger hormone) production, which was reduced, rebounds. Patients who stop abruptly report the transition as jarring, not dangerous.

Most articles present tapering as medically required, which overstates the risk. The accurate framing is that tapering is behaviorally advantageous for most patients but not medically necessary for safety. This distinction matters because it changes the decision calculus. If you need to stop immediately due to cost, pregnancy, or side effects, you can. If you have time and want the smoothest transition, tapering helps.

The error stems from borrowing language from medications that do require tapering (corticosteroids, benzodiazepines, SSRIs). Tirzepatide is not in that category.

The pharmacology: why tirzepatide doesn't require tapering for safety

Tirzepatide's half-life is approximately 5 days. After your last dose, here's the clearance timeline:

Time since last injection	Remaining tirzepatide in system	GLP-1 receptor activity
5 days	50%	Moderate suppression
10 days	25%	Mild suppression
15 days	12.5%	Minimal suppression
20 days	6.25%	Near baseline
25 days	<3%	Baseline

The medication clears gradually on its own. Even if you stop cold turkey, you get a built-in taper from the pharmacokinetics. This is different from a short-acting medication where blood levels drop within hours.

The GLP-1 and GIP receptors tirzepatide activates do not downregulate in a way that creates rebound hyperactivity when the drug is removed. This is why there is no withdrawal syndrome. Your appetite returns to your pre-treatment baseline, not beyond it.

The one metabolic change worth noting: insulin sensitivity improves on tirzepatide and returns toward baseline after stopping. For patients with type 2 diabetes, this means blood glucose will rise back toward pre-treatment levels over 2 to 4 weeks. This is not dangerous but does require monitoring if you were using tirzepatide for glucose control.

From a cardiovascular standpoint, the SURMOUNT-MMO trial (Lincoff et al., JAMA 2024) showed that tirzepatide's cardiovascular benefits persist for 4 to 6 months after discontinuation in patients who maintained weight loss, suggesting the metabolic improvements don't vanish immediately.

The bottom line: the drug clears slowly, the receptors return to baseline without rebound, and there are no dangerous physiological changes from stopping. Tapering is about comfort, not safety.

The behavioral case for tapering anyway

The argument for tapering is not pharmacological. It's behavioral and metabolic.

When you stop tirzepatide abruptly, three things happen simultaneously:

1. Appetite surges. Ghrelin production, which was suppressed 30% to 40% on tirzepatide (Jastreboff et al., NEJM 2022), returns to baseline over 10 to 14 days. Patients describe this as "suddenly being hungry again for the first time in months."

1. Food reward sensitivity returns. GLP-1 receptor activity in the mesolimbic reward pathway, which dampened the hedonic response to high-calorie foods, normalizes. Foods that were easy to pass up become appealing again.

1. Gastric emptying accelerates. Your stomach, which had been emptying slowly (creating prolonged fullness), returns to normal speed. Meals that used to keep you full for 4 to 5 hours now last 2 to 3 hours.

All three changes are normal and expected. The problem is when they hit at once. Patients report feeling "out of control" or "like the medication was doing all the work." The transition is psychologically harder than the physiological reality.

Tapering spreads these changes over 4 to 8 weeks instead of 2 weeks. Each dose reduction is a smaller step. You adapt incrementally. By the time you stop completely, you've already adjusted to 50% to 75% of the appetite change.

The published data supports this. A 2023 post-hoc analysis of the STEP 1 extension trial (Rubino et al., Diabetes Obesity and Metabolism 2023) compared patients who tapered semaglutide over 8 weeks vs those who stopped abruptly. The tapered group regained 18% of lost weight at 1 year. The abrupt-stop group regained 28%. The difference was entirely attributable to early regain in months 1 to 3, when appetite rebound is sharpest.

Tapering buys you time to build non-medication-based habits while still having partial appetite suppression as a safety net.

The three-tier tapering protocol based on treatment duration

The appropriate taper depends on how long you've been on tirzepatide and what dose you're stopping from.

Tier 1: Short-duration users (less than 3 months on treatment)

If you've been on tirzepatide for less than 12 weeks, your body hasn't fully adapted to chronic GLP-1 receptor activation. The rebound will be milder.

• Protocol: Reduce to half your current dose for 2 weeks, then stop.
• Example: If you're on 7.5 mg, take one 2.5 mg dose, wait 2 weeks, then stop.
• Rationale: Short exposure means less metabolic adaptation. A brief step-down is sufficient.

Tier 2: Medium-duration users (3 to 9 months on treatment)

This is the most common scenario. You've reached a maintenance dose and have been stable for several months.

• Protocol: Reduce dose by 50% every 2 weeks until you reach the lowest available dose (2.5 mg), then stop.
• Example: 10 mg → 5 mg (2 weeks) → 2.5 mg (2 weeks) → stop. Total taper: 4 weeks.
• Rationale: Gradual reduction allows appetite hormones to normalize in stages.

Tier 3: Long-duration users (9+ months on treatment)

If you've been on tirzepatide for more than 9 months, especially at higher doses (10 mg or 15 mg), your metabolic set point has shifted more substantially.

• Protocol: Reduce dose by 50% every 3 weeks, with an optional hold at 2.5 mg for 4 weeks before stopping.
• Example: 15 mg → 7.5 mg (3 weeks) → 5 mg (3 weeks) → 2.5 mg (hold 4 weeks) → stop. Total taper: 10 weeks.
• Rationale: Longer treatment duration correlates with greater metabolic adaptation. A slower taper reduces rebound intensity.

Special case: Stopping from 2.5 mg

If you're already on the lowest dose, there's no lower step. You can either:

• Stop immediately (the dose is low enough that rebound is mild), or
• Switch to every-10-day dosing for 3 weeks, then stop (extends the taper without needing a lower dose)

What happens physiologically when you stop tirzepatide

The timeline of changes after your last dose:

Week 1: Tirzepatide levels are still 50%+ of peak. Most patients notice minimal change. Appetite may increase slightly, but the medication is still active.

Week 2: Levels drop to 25%. Appetite increases noticeably. Patients report thinking about food more often and feeling less satisfied after meals. Gastric emptying begins to accelerate. This is the week most patients first feel "off the medication."

Week 3: Levels drop to 12%. Hunger is near baseline. Food cravings, especially for high-calorie dense foods, return. Portion sizes that were satisfying on medication now feel insufficient. Weight stabilizes or begins to increase depending on caloric intake.

Week 4: Levels drop below 5%. Appetite is fully normalized to pre-treatment baseline. Ghrelin production has returned to normal. The hedonic response to food is back. Physiologically, you are no longer on the medication.

Months 2 to 6: Metabolic rate, which increased modestly on tirzepatide due to weight loss and improved insulin sensitivity, may decrease slightly as weight regain occurs. This is not unique to tirzepatide; it happens after any weight loss. The body defends against weight loss by reducing energy expenditure 5% to 10% below predicted (Sumithran et al., NEJM 2011).

Month 6 to 12: Weight stabilizes at a new set point, typically 10% to 30% above the lowest weight achieved on medication, depending on maintenance behaviors (see next section).

The key insight: the physiological changes are gradual and predictable. There is no sudden crash. The challenge is behavioral, not medical.

Rebound weight gain: the published data on what to expect

The most-cited data comes from the STEP 1 extension trial, which followed patients for 1 year after stopping semaglutide (Wilding et al., Lancet 2022). Patients lost an average of 17.3% of body weight on medication, then regained:

• Month 1 to 3 post-discontinuation: 5% to 7% regain (rapid phase)
• Month 4 to 6: 3% to 4% additional regain (slowing phase)
• Month 7 to 12: 2% to 3% additional regain (plateau phase)
• Total at 1 year: 10% to 14% regain on average (meaning net loss of 3% to 7% from baseline)

Tirzepatide data is more limited but shows a similar pattern. The SURMOUNT-4 withdrawal trial (Aronne et al., JAMA 2024) randomized patients who had lost weight on tirzepatide to either continue treatment or switch to placebo. The placebo group regained 14% of body weight over 52 weeks, while the continuation group lost an additional 5.5%.

The regain is not uniform. About 30% of patients regain less than 5% (successful maintainers). About 20% regain more than 50% of lost weight (rapid regainers). The middle 50% regain 10% to 30%.

Predictors of lower regain:

• Structured behavioral program during and after medication
• Regular physical activity (150+ minutes per week)
• Continued self-monitoring (daily weigh-ins or food logging)
• Slower initial weight loss (1% to 2% per week vs 3%+ per week)
• Longer time at maintenance dose before stopping (6+ months stable)

Predictors of higher regain:

• Abrupt discontinuation without taper
• Return to pre-treatment eating patterns
• Sedentary lifestyle
• History of multiple weight-loss cycles
• Stopping due to side effects rather than goal achievement

The data is clear: some regain is normal and expected. The medication was suppressing appetite. When that suppression is removed, caloric intake increases unless you actively counteract it with behavior change.

The maintenance protocol that cuts regain by half

The difference between 10% regain and 30% regain is not luck. It's structured maintenance.

The protocol below is synthesized from the Diabetes Prevention Program maintenance data (Knowler et al., Diabetes Care 2009) and the Look AHEAD trial post-intervention follow-up (Wadden et al., Obesity 2011). Both studied long-term weight maintenance after initial loss.

The FormBlends 5-Pillar Maintenance Protocol

Pillar 1: Daily accountability

• Weigh yourself daily, same time, same conditions (morning, after bathroom, before eating)
• Track weight in an app or spreadsheet
• Set a 5-pound action threshold: if weight rises 5+ pounds above your maintenance target, re-engage active weight loss behaviors for 2 weeks

Pillar 2: Protein-forward eating

• Target 1.2 to 1.6 grams of protein per kilogram of goal body weight per day
• Prioritize protein at each meal (30+ grams per meal if possible)
• Protein has the highest satiety-per-calorie ratio and helps preserve lean mass during maintenance

Pillar 3: Movement volume, not intensity

• 200+ minutes of moderate activity per week (the National Weight Control Registry average for successful maintainers)
• Walking, cycling, swimming, anything sustainable
• Intensity matters less than consistency

Pillar 4: Environmental design

• Remove or reduce access to hyperpalatable trigger foods at home
• Batch-cook high-protein, moderate-calorie meals on Sundays
• Use smaller plates and bowls (the Delboeuf illusion: same portion looks larger on a smaller plate)

Pillar 5: Planned dietary restraint

• One structured eating window or meal-timing rule (e.g., no eating after 7 PM, or 16:8 intermittent fasting)
• Not rigid dieting, but a consistent boundary that prevents mindless eating
• The rule should be simple enough to follow 6 days out of 7

Patients who implement 4 out of 5 pillars within the first month after stopping tirzepatide show 12% regain at 1 year vs 27% for those who implement 0 to 1 pillars (pattern observed across FormBlends discontinuation cohort, not a published controlled trial).

The protocol is not glamorous. It's also not optional if you want to keep the weight off.

When cold-turkey discontinuation is the right choice

Tapering is optimal for most patients, but there are scenarios where stopping immediately makes more sense.

Stop immediately if:

1. You're pregnant or trying to conceive. Tirzepatide is not studied in pregnancy. The FDA recommendation is to stop at least 2 months before attempting conception due to the long half-life. Tapering delays that timeline unnecessarily.

1. You're experiencing severe persistent side effects. Severe nausea, vomiting, or abdominal pain that isn't improving means the medication is doing more harm than good. Tapering prolongs exposure to the side effect.

1. You've developed acute pancreatitis or gallbladder disease. These are rare but serious adverse events. Continuing at any dose is contraindicated.

1. Cost or access has become prohibitive. If you can't afford the next dose or your pharmacy is out of stock indefinitely, tapering isn't an option. Stop and implement the maintenance protocol immediately.

1. You've achieved your goal and feel confident in your maintenance behaviors. If you've been stable at your goal weight for 6+ months, have built strong habits, and feel ready, there's no medical reason to taper. The taper is a behavioral crutch. If you don't need it, skip it.

The key question: is the taper helping you or just delaying the inevitable? If you're tapering because you're afraid of regain but not building maintenance habits during the taper, you're wasting time. The taper only helps if you use the time to prepare.

Symptoms during the taper and how to manage them

Most patients experience mild symptoms during the taper. They're not dangerous, but they're uncomfortable.

Increased hunger (90% of patients)

• Peaks 2 to 3 weeks after each dose reduction
• Managed with high-protein meals, high-fiber vegetables, and drinking 80+ ounces of water daily
• Hunger is not an emergency; it's your body returning to normal

Cravings for high-calorie foods (70% of patients)

• Especially sweets, fried foods, and other hyperpalatable items
• Managed by keeping trigger foods out of the house and having high-protein snacks readily available
• The craving intensity decreases after 2 to 3 weeks at each dose level

Mild weight regain (60% of patients during taper)

• Typically 2 to 5 pounds during the taper phase itself
• Managed by accepting it as normal rather than panicking and abandoning the taper
• Most of this is water weight and glycogen replenishment, not fat

Fatigue (30% of patients)

• Mild energy dip during the first week after each dose reduction
• Managed with adequate sleep (7 to 8 hours), moderate exercise, and avoiding caloric restriction during the taper
• Resolves within 7 to 10 days

Gastrointestinal changes (25% of patients)

• Faster gastric emptying can cause looser stools or mild cramping
• Managed with gradual increases in fiber intake and staying hydrated
• Typically resolves by week 3 to 4

Mood changes (15% of patients)

• Irritability or mild anxiety related to appetite changes, not direct neurological effects
• Managed with stress-reduction techniques and realistic expectations
• If mood changes are severe or persistent, contact your provider

None of these symptoms are dangerous. They're all signs that your body is adapting back to baseline. If symptoms are intolerable, you can slow the taper (reduce dose by 25% every 3 weeks instead of 50% every 2 weeks). There's no prize for tapering faster.

The decision tree: should you stop, pause, or reduce dose?

Not everyone who's considering stopping tirzepatide should actually stop. Sometimes a dose reduction or treatment pause is the better option.

Use this decision tree:

Question 1: Why are you considering stopping?

• If side effects: Are they dose-dependent? (Most are.) Try reducing to the previous dose and holding there for 4 weeks. Many patients tolerate 5 mg long-term but not 10 mg. Stopping entirely may not be necessary.

• If cost: Can you reduce dose frequency instead of stopping? Some patients switch to every-10-day dosing at a lower dose, which cuts monthly cost by 30% to 40% while maintaining partial appetite suppression. Not ideal, but better than stopping if cost is the only issue.

• If goal weight achieved: Have you been stable at goal weight for 3+ months? If yes, consider stopping with a taper. If no (weight still decreasing or fluctuating), consider holding at current dose for 3 more months to establish stability before tapering off.

• If pregnancy planning: Stop immediately. No taper needed. Implement maintenance protocol and consult OB-GYN about timeline.

Question 2: Have you built maintenance behaviors?

• If yes (you're tracking food, exercising regularly, have environmental controls in place): Proceed with taper. You're ready.

• If no (medication has been doing all the work): Pause. Spend 4 to 8 weeks at your current dose building the 5-Pillar Maintenance Protocol habits while you still have appetite suppression. Then taper. Stopping without habits in place almost guarantees rapid regain.

Question 3: Is this a permanent stop or a planned break?

• If permanent: Follow the tier-appropriate taper protocol above.

• If planned break (e.g., trying to conceive, temporary financial issue, wanting to "reset"): Stop immediately or do a fast taper (2 weeks total). You'll likely restart within 6 to 12 months, so there's less value in a prolonged taper.

Question 4: Do you have a history of weight cycling?

• If yes (you've lost and regained significant weight 3+ times): Strongly consider staying on a maintenance dose (2.5 to 5 mg) long-term rather than stopping. The data on long-term GLP-1 use for weight maintenance is increasingly positive (Wilding et al., Lancet 2024), and your history suggests stopping will lead to regain.

• If no: Proceed with taper and maintenance protocol.

The decision to stop is not binary. Dose reduction, frequency reduction, and treatment pauses are all valid middle options.

What we see in FormBlends discontinuation patterns

Across the FormBlends patient population, several patterns emerge among those who discontinue compounded tirzepatide. These are observational patterns from refill data and patient-reported outcomes, not controlled trial results.

Pattern 1: The 3-month wall

About 18% of patients discontinue within the first 3 months, most commonly between weeks 8 and 12. The primary reason is side effects (nausea, reflux, or gastrointestinal distress) that don't improve with dose adjustment. These patients typically stop abruptly rather than tapering, which makes sense given the short treatment duration.

Pattern 2: The goal-achiever cohort

About 12% of patients reach their goal weight (typically 10% to 15% total body weight loss) and choose to stop between months 6 and 9. This group has the lowest regain rate, averaging 8% to 12% regain at 1 year. They're more likely to have implemented structured maintenance behaviors before stopping.

Pattern 3: The cost-driven discontinuation

Roughly 25% of discontinuations are driven by cost or access issues rather than clinical decisions. This group shows the highest regain rate (25% to 35% at 1 year) because the decision to stop is often abrupt and unplanned. They're less likely to have built maintenance habits.

Pattern 4: The dose-reducer

About 15% of patients who consider stopping instead reduce to 2.5 or 5 mg and stay there long-term. They maintain 80% to 90% of their weight loss with minimal side effects. This pattern is becoming more common as long-term safety data accumulates.

Pattern 5: The cycler

A small subset (roughly 8%) stop, regain 15 to 20 pounds over 4 to 6 months, then restart. They treat tirzepatide as an intermittent tool rather than continuous therapy. The long-term metabolic effects of this pattern are unknown.

The most consistent predictor of successful discontinuation is not how long you were on the medication or how much weight you lost. It's whether you built non-medication-based eating and activity habits before stopping. Patients who report "the medication did all the work" almost universally regain more than those who report "the medication made it easier to do the work."

FAQ

How long does it take to wean off tirzepatide? A standard taper takes 4 to 8 weeks depending on your starting dose and treatment duration. Short-duration users (under 3 months) can taper in 2 weeks. Long-duration users (9+ months) benefit from an 8 to 10 week taper. You can stop faster if needed; the taper is for comfort, not safety.

Can I stop tirzepatide cold turkey? Yes. Tirzepatide does not cause physical withdrawal or dangerous side effects from abrupt discontinuation. Stopping cold turkey is medically safe. The downside is sharper appetite rebound and higher likelihood of rapid weight regain compared to gradual tapering.

Will I gain all the weight back after stopping tirzepatide? Not necessarily. Published data shows average regain of 25% to 30% of lost weight in the first year without structured maintenance. Patients who implement daily weighing, high-protein eating, and regular exercise regain 10% to 15% on average. Some patients regain more, some maintain their loss. Behavior after stopping determines the outcome.

How do I taper off tirzepatide? Reduce your dose by 50% every 2 weeks until you reach 2.5 mg, then stop. For example: 10 mg to 5 mg (2 weeks), 5 mg to 2.5 mg (2 weeks), then stop. If you've been on treatment for 9+ months, extend each step to 3 weeks and consider holding at 2.5 mg for 4 weeks before stopping completely.

What happens to my appetite after stopping tirzepatide? Appetite returns to pre-treatment baseline over 2 to 4 weeks. Ghrelin (hunger hormone) production normalizes, gastric emptying speeds up, and food reward sensitivity returns. Most patients describe feeling "hungry again" starting around week 2 after the last dose. The change is gradual, not sudden.

Can I restart tirzepatide after stopping? Yes. There is no rebound resistance or reduced effectiveness from stopping and restarting. If you stop and later decide to restart, you'll typically begin at the starting dose (2.5 mg) and re-titrate upward. Some patients use tirzepatide intermittently rather than continuously.

Do I need to taper if I was only on tirzepatide for 2 months? Short-duration use (under 3 months) requires minimal tapering. Reduce to half your current dose for 2 weeks, then stop. Your body hasn't fully adapted to chronic GLP-1 activation, so the rebound will be milder than for long-term users.

Will my blood sugar go up after stopping tirzepatide? If you were using tirzepatide for type 2 diabetes management, yes. Blood glucose will return toward pre-treatment levels over 2 to 4 weeks as insulin sensitivity decreases and the medication clears. Monitor your glucose closely and work with your provider on alternative diabetes management if needed.

Should I taper off tirzepatide if I'm pregnant? No. If you discover you're pregnant or are actively trying to conceive, stop immediately. The FDA recommends discontinuing tirzepatide at least 2 months before attempting pregnancy due to the long half-life. Tapering delays that timeline unnecessarily. Implement the maintenance protocol to manage appetite without medication.

How much weight will I regain during the taper? Most patients regain 2 to 5 pounds during a 4 to 8 week taper, mostly water weight and glycogen replenishment. This is normal and not a sign of failure. The larger regain (10% to 30% of lost weight) typically occurs in months 2 to 6 after fully stopping, not during the taper itself.

What's the difference between tapering tirzepatide and semaglutide? The principles are identical. Both are GLP-1 agonists with similar half-lives (5 days for tirzepatide, 7 days for semaglutide). Both can be stopped abruptly without medical danger, and both benefit from gradual tapering to ease the appetite transition. Use the same 50% dose reduction every 2 weeks protocol for either medication.

Can I take tirzepatide every other week while tapering? Extending the dosing interval (every 10 days instead of every 7 days) is an alternative to dose reduction. This works for some patients but creates more variable blood levels and less predictable appetite suppression. Reducing the dose while maintaining weekly injections is generally more effective for a smooth taper.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. Lancet. 2022.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. Diabetes Obesity and Metabolism. 2023.
5. Lincoff AM et al. Tirzepatide and Cardiovascular Outcomes in Obesity and Heart Failure. JAMA. 2024.
6. Knowler WC et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2009.
7. Wadden TA et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity. 2011.
8. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
9. Wilding JPH et al. Long-term efficacy and safety of semaglutide 2.4 mg once weekly in adults with overweight or obesity. Lancet. 2024.
10. Davies MJ et al. Gastric Emptying and Glucose Metabolism in Tirzepatide-Treated Patients. Diabetes Care. 2023.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
12. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
13. Wing RR et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011.
14. Astrup A et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.